- COMMUNITY OUTREACH AND ENGAGEMENT (COE) The Ohio State University Comprehensive Cancer Center (OSUCCC) is a national and international leader in translational research, with a reputation for delivering high-quality patient care and effective outreach and education programs to residents of the state of Ohio - our catchment area (CA) - and beyond. The CA includes all 88 counties in Ohio, which have very diverse populations, with many underserved communities as well as urban, rural and Appalachian communities. Electra Paskett, PhD, MSPH (CC) Associate Director for Population Science and Community Outreach and Director of the Center for Cancer Health Equity (CCHE) leads the Community Outreach and Engagement (COE) efforts for the OSUCCC. The CCHE is at the core of our COE efforts supporting the OSUCCC mission to reduce cancer health disparities throughout the CA. The CCHE is co- led by Darrell Gray II, MD, MPH, FACG (CC), who oversees the COE initiatives with the Clinical Trials Office to improve the accrual of women and minorities to clinical trials. COE works in the CA to connect minority populations to screening, outreach and engagement services. They also work with basic, clinical and population science program leaders in the OSUCCC to cultivate interest in CA-focused research including working with the Government Relations team and key faculty across the Center to pursue policy initiatives that address the cancer burden. COE efforts are supported by two Community Advisory Boards (rural and urban) that inform the focus and scope of CCHE activities and provide ongoing feedback to the OSUCCC leadership and Program leaders. The high priority cancers for the OSUCCC include lung, breast, colorectal, prostate, endometrial, cervical cancer, thyroid, and leukemia, as well as tobacco use, obesity and HPV vaccination. OSUCCC research and/or outreach and engagement efforts are ongoing to address these priority areas, via partnerships between the COE, OSUCCC research program members, and the community. To assess the impact of COE and OSUCCC efforts we have developed a logic model that includes short-term metrics of COE success: expanded reach (community members, patients); impact (services provided, time to diagnosis); collaborations (community partners, researchers); initiatives (grants funded); and clinical trial accrual (especially of underrepresented populations); and long-term metrics success including: reduced prevalence of risk factors and cancer rates, and longevity and impact of community partnerships. Over the last five years, we have had significant impact on HPV vaccination rates, accrual of minorities to clinical trials, breast cancer detection rates, navigation to screening and treatment, implementing translation for non-English speaking patients, fostering research to address the cancer burden in the CA. COE future plans focus on the priority cancers/risk behaviors of the OSUCCC as well as on 1) ensuring adequate communication between the community and the OSUCCC researchers as it relates to addressing the cancer burden in the catchment area and 2) a focus across the lifespan and expand to populations we are just beginning to work with (Asian, pediatric, rural clinics, LGBTQ) in order to reduce the cancer burden in our CA.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089998
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nakashima, Hiroshi; Alayo, Quazim A; Penaloza-MacMaster, Pablo et al. (2018) Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. Sci Rep 8:208
Coss, Christopher C; Clinton, Steven K; Phelps, Mitch A (2018) Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy? Clin Cancer Res 24:5787-5789
Rogers, Kerry A; Huang, Ying; Ruppert, Amy S et al. (2018) Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. Blood 132:1568-1572
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia 32:1338-1348
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Salzer, Wanda L; Burke, Michael J; Devidas, Meenakshi et al. (2018) Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer 124:1150-1159
Yu, Peter Y; Lopez, Gonzalo; Braggio, Danielle et al. (2018) miR-133a function in the pathogenesis of dedifferentiated liposarcoma. Cancer Cell Int 18:89
Eisfeld, Ann-Kathrin; Kohlschmidt, Jessica; Mrózek, Krzysztof et al. (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32:2536-2545
Sprague, Leslee; Lee, Joel M; Hutzen, Brian J et al. (2018) High Mobility Group Box 1 Influences HSV1716 Spread and Acts as an Adjuvant to Chemotherapy. Viruses 10:
Koster, Roelof; Panagiotou, Orestis A; Wheeler, William A et al. (2018) Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. Int J Cancer 142:1594-1601

Showing the most recent 10 out of 2602 publications